CordLife India ties up with Duke Medicine to treat autism


Pioneer Founding member

CordLife India, a stem cell banking company, has taken an initiative to assist autistic patients who have stored their cord blood.

The company is extending its support to link patients in India in association with Duke Medicine research programme for such treatment.

Duke Medicine has been awarded $15 million to support an innovative research programme that explores the use of umbilical cord blood stem cells to treat autism, stroke, cerebral palsy and related brain disorders.

“Over the years, we have earned the trust of the parents to store their baby’s precious cord blood and cord lining with us. The Duke’s medicine research programme confirms our long held beliefs that the potential for future use of cord blood and cord lining will grow with the advancement in cell therapy,” Jeremy Yee, Chief Executive Officer of CordLife, was quoted in a release issued by the company.

The release says US data suggest that approximately one out of 50 babies suffer from autistic spectrum disorder. Boys are said to be five times more likely to have than girls. Treating autism costs $60,000 in a year on an average.

(This article was published on November 20, 2014)